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The most important genes responsible for the onset of type 1 dia-
betes mellitus (T1DM) are those encoding the class II MHC alleles 
(1–3). In particular, the biochemical features of diabetogenic class 
II MHC molecules determine binding of autoantigenic peptides 
that ultimately trigger islet β cell–reactive T cells. In both humans 
and NOD mice (4), a notable feature of diabetes-related class II 
MHC alleles is the expression of a nonaspartic acid residue at 
position 57 of the β chain: an alanine in the case of the human 
HLA-DQ2 and HLA-DQ8 molecules (hereafter referred to as DQ2 
and DQ8, respectively) and a serine in the case of the NOD class II 
MHC molecule I-Ag7 (5–7). In contrast, most other class II MHC 
alleles express a conserved aspartic acid at β57 that pairs with an 
arginine at α76, defining the position 9 (P9) pocket of the peptide 
binding groove. Moreover, in humans, there are other alleles, such 
as HLA-DR3 and HLA-DR4, that in association with the DQ mol-
ecules increase the genetic risk for T1DM (8, 9).
The structure of both the I-Ag7 (10, 11) and DQ8 (12) molecules 
was solved by x-ray crystallography. I-Ag7 showed a P9 anchor 
pocket that was shallow, wide, and more open toward the C ter-
minus as a result of the β57Ser and β56His. Subsequent studies 
established that the P9 pocket was most crucial in determining the 
selection of peptides during processing of natural proteins by APC 
(13, 14). Peptides selected by I-Ag7 contained acidic-rich C termini 
that interacted with the P9 pocket and often contained multiple 
C-terminal acidic residues that increased their binding affinity 
(13). APCs expressing a modified I-Ag7, wherein the β57Ser was 
changed to the conserved aspartic acid, did not favor peptides with 
C-terminal acidic residues (13).
Wiley’s group resolved the protein crystal structure of the DQ8 
molecule bound to an insulin peptide, demonstrating the simi-
larities of its P9 pocket to that of I-Ag7 (12). However, the spatial 
and biochemical features of the other binding pockets of DQ8 
are distinct. The DQ8 P4 pocket is very large and accommodates 
bulky residues such as tyrosines, while in I-Ag7, it is shallow and 
favors small to medium-sized hydrophobic residues, disfavoring 
large, bulky residues. Similarly, the P1 pocket of DQ8 contains an 
arginine at α52 (in contrast to an isoleucine in the case of I-Ag7), 
which forms an ion pair with an acidic amino acid from the 
peptide at P1. Our previous studies on peptide selection by I-Ak, 
which also contains α52Arg, revealed that most of the high-affin-
ity peptides selected by this haplotype contained an acidic residue 
at P1 (15, 16). Thus, with respect to the P1 pocket, DQ8 resembles 
I-Ak more closely than I-Ag7. However, the precise contribution of 
each of these pockets in influencing the repertoire of peptides 
selected by DQ8 remains unclear.
Previous studies analyzing naturally processed peptides selected 
by human diabetogenic class II MHC molecules are limited and 
have given ambiguous results. In the first study by Chicz et al., 
few peptides were identified from DQ8 APCs ranging from 13–74 
amino acids in length. These did not exhibit a consensus binding 
motif and were not analyzed extensively for their binding features 
(17). A second study, by Godkin et al., utilized pool sequencing 
to identify DQ8-bound peptides. This report suggested the pres-
ence of both acidic and basic amino acids at P4 (aspartic acid), 
P6 (arginine), and P9 (arginine and glutamic acid) (18). Concern-
ing the peptide binding motif for DQ8 and DQ2, some reports 
suggested the preference for an acidic P9 anchor, while others did 
not (17–29). Moreover, recent reports examining binding with syn-
thetic peptides indicated that the murine and human diabetogenic 
molecules bound epitopes of various specificity (24, 30, 31).
Information on the peptides naturally selected during pro-
cessing will help in understanding the role of MHC in autoim-
munity as well as in predicting potential diabetogenic peptides. 
Nonstandard	abbreviations	used: MS, mass spectrometry; MS/MS, tandem mass 
spectrometry; P9, position 9; SCX, strong cation exchange; TFA, trifluoroacetic acid.
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Naturally processed peptides represent the physiological sub-
stratum for CD4 T cell recognition: they represent what the APC 
prefers to select and display to the extracellular milieu. What are 
the chemical features of the natural peptides bound and selected 
by DQ8 molecules during the processing of self proteins? What 
are the binding motifs of such naturally selected peptides and 
the anchor residues that contribute to binding and selection? Are 
there peptide families that are naturally selected by both DQ8 
and I-Ag7 molecules, and if so, is the mode of binding identical 
between the two? To answer these basic questions in a defini-
tive way, we isolated naturally processed peptides from APC 
lines expressing either DQ8 or I-Ag7. The APC lines were identi-
cal, except for the class II molecules, which allowed us to directly 
compare the repertoire of peptides selected by them. The large 
data sets of naturally processed peptides indicated a high degree 
of specificity of peptide selection exhibited by DQ8 — of note was 
the presence of multiple C-terminal acidic residues especially at 
P9 and to a lesser degree at P1. In contrast to results of studies 
using synthetic peptide libraries, there was little peptide promis-
cuity for DQ8 or for I-Ag7 proteins. We provide the first direct 
evidence that identical peptide families were naturally selected by 
both DQ8 and I-Ag7 and bound in the same register, which indi-
cates a common biochemical outcome of the antigen processing 
and presentation pathways.
Results
Generation and characterization of APC lines
APC lines were generated on identical genetic backgrounds 
expressing either DQ8 or I-Ag7 (Table 1). FACS analysis indi-
cated that the I-Ag7–expressing NOD.C3 cell line had about 
8-fold more cell surface class II MHC molecules than the NOD.
DQ8 cell line (Figure 1). This difference in class II MHC levels 
also correlated with the amounts of peptides recovered from 
each cell line; i.e., more peptides were isolated from I-Ag7 than 
from DQ8 (Supplemental Tables 1 and 2, and see following sec-
tions; supplemental material available online with this article; 
doi:10.1172/JCI25350DS1).
Features of naturally processed peptides
Naturally selected peptides, from I-Ag7 and DQ8, were isolated and 
sequenced by tandem mass spectrometry (MS/MS) analyses. The 
class II MHC molecules select for peptides in “families,” each shar-
ing a common 9-amino-acid core, which interacts with the MHC 
binding groove from P1 to P9, along with varying lengths of flank-
ing residues in the N and C termini (for example, see refs. 13, 32). 
A total of 206 peptides representing 108 families were isolated 
from DQ8 (Table 2 is a summary; the entire library of peptides is 
presented in Supplemental Table 1). We previously reported on 
I-Ag7–bound peptides but repeated the isolation in the current 
study in order to compare experiments done with the same cell 
line and in parallel with the examination of peptides from DQ8: 
301 peptides representing 115 distinct families were isolated from 
I-Ag7 (Table 3 is a summary; Supplemental Table 2 includes all the 
information). Peptides from both were derived from proteins pres-
ent on the cell membrane, vesicular compartment, and cytosol, as 
well as the extracellular milieu.
Interestingly, 18 of the 108 peptide families (or 17%) from DQ8 
were also selected by I-Ag7 (Table 4 and marked by asterisks in 
Supplemental Table 1). The abundance of some of the common 
peptide families was comparable in the 2 molecules, while others 
were dominant in one compared with the other (see Supplemen-
tal Tables 1 and 2). For example, from DQ8, 7 members of the 
E2B 112–126 peptide family were identified, while from I-Ag7, 
16 members were sequenced (Supplemental Tables 1 and 2). 
Nonetheless, the finding of common peptide families in I-Ag7 
and DQ8 was especially surprising, since both proteins exhibit 
only 60–70% similarity at the amino acid level between their α 
and β chains. In contrast, I-Ag7 is approximately 94% similar to 
I-Ad, but the naturally processed peptides selected by each were 
entirely distinct (13, 14). Moreover, peptides selected by a mutant 
I-Ag7 molecule called I-Ag7PD, in which residues 56 and 57 of the 
β chain were replaced by those from the I-Ad allele, did not over-
lap with those selected by I-Ag7 (13). Note that most of the com-
mon peptides exhibited the presence of an acidic amino acid at 
P9 (Table 4). The relevance of this observation with regard to the 
binding motif is discussed in the following section.
Binding motif: DQ8 versus I-Ag7
The naturally processed peptides from DQ8 and I-Ag7 were aligned 
on the basis of a favorable 9-mer core (as shown in Supplemental 
Tables 1 and 2). The compiled results of such analyses established 
the preferred binding motif for both diabetogenic class II MHC 
molecules, which we detail below. DQ8 and I-Ag7 selected for pep-
tides that contained acidic amino acids toward their C terminus 
(Figure 2). Many peptides from both contained runs of double or 
triple acidic residues toward the C terminus. It was shown pre-
viously that multiple C-terminal acidic residues cooperated to 
increase peptide binding affinity to I-Ag7 (13). In addition, DQ8 
Table 1
Class II MHC molecules and background genes of cell lines
APC	 Class	II	MHC	 β57	 Background
NOD.C3 I-Ag7 Ser NOD
NOD.DQ8 DQ8 Ala NOD
APC lines were generated by fusion of LPS-activated splenocytes 
from NOD or transgenic NOD.DQ8 mice to the M12.C3 B cell lym-
phoma partner line.
Figure 1
Class II MHC expression among APC lines. NOD.C3 and NOD.DQ8 
cells were stained with anti–I-Ag7 or anti-DQ8 mAb (gray lines), respec-
tively, and then analyzed by FACS. Black lines indicate the isotype 
control for each cell line.
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also showed a slight preference for acidic amino acids at the N 
terminus (Figure 2), a finding consistent with the biochemical 
features of the P1 pocket of DQ8 discussed above (12).
The relative abundance for naturally processed peptides select-
ed by DQ8 varied greatly: the most abundant peptide family was 
1,200-fold more abundant than the least; similarly, for I-Ag7, the 
difference was about 3,000-fold (see Supplemental Tables 1 and 
2 for abundance). There was also no relationship between the 
abundance of peptides and their binding motifs (Supplemental 
Tables 1 and 2); i.e., peptide families with favorable binding cores 
were present in varying amounts. In addition, binding affinity also 
did not correlate with abundance, for example, even though the 
peptide from superoxide dismutase 1 protein 90–103 bound about 
15-fold better to DQ8 than the epitope from DQ α chain 39–52, 
it was present in one-tenth the amount of the DQ α chain peptide 
(Table 5 and Supplemental Table 1; see also the following section). 
Similar results were obtained in our earlier analysis of peptides 
bound to I-Ag7, I-Ad, I-Ag7PD, and I-Ak (13, 14) and in the analysis of 
class I MHC peptides by Engelhard’s laboratory (33) and ours with 
Kd-bound peptides. Other parameters such as the levels of protein 
expression, their turnover rates, and their accessibility to the MHC 
pathways of antigen processing and presentation must impact 
the final outcome of abundance and peptide selection. These fea-
tures may become very relevant in situations of pathogen-specific 
immune responses or autoimmune responses.
DQ8 binding motif. The P1 pocket of DQ8 exhibited a preference 
for acidic amino acids (about 42% of residues at P1 were either glu-
tamic acid or aspartic acid; Figure 3A), which was consistent with the 
structural aspects. Besides these, the P1 pocket also accommodated a 
variety of residues with the noticeable exception of basic amino acids, 
which would be electrostatically disfavored at this position. P4 was 
dominated by small hydrophobic or polar residues — alanine, serine, 
glycine, and threonine constituted 53% of amino acids at P4; while 
P6 favored alanine, valine, and serine, which made up 52% of the 
residues (Figure 3A). The P9 pocket of DQ8 was almost exclusively 
dominated by acidic amino acids — 84% of them (Figure 3A).
I-Ag7 binding motif. P1 of I-Ag7 accommodated a variety of residues, 
including polar, charged, and hydrophobic amino acids. P4 and P6 
were dominated by the presence of small to medium-sized hydropho-
bic amino acids in addition to polar residues (leucine, isoleucine, and 
valine represented more than 60% of amino acids at P4; while alanine, 
serine, valine, and glycine represented more than 60% of residues at 
P6) (Figure 3B). Both P4 and P6 disfavored bulky or basic amino 
acids. P9 was highly biased for the presence of acidic amino acids 
(∼90% of residues at P9 were glutamic acid or aspartic acid; Figure 3B), 
results that are akin to those of our prior studies (13, 14).
Binding analyses
All 14 peptides tested in the binding assay bound to soluble DQ8, 
which confirmed that these were bona fide epitopes selected by 
Table 2
Examples of naturally processed peptides selected by DQ8
Peptide	 	 	 	 	 1	 	 	 4	 	 6	 	 	 9
E25B protein 112–126 Y Q T I E E N I K I F E E D A
Superoxide dismutase 90–103  A G K D G V A N V S I E D R
TRAIL receptor 2 364–380 G R F T Y Q N A A A Q P E T G P G
Lamp I 129–144 I Y T M D S T T D I K A D I N K
Transferrin receptor 334–347  I P V Q T I S R A A A E K L
Cyclophilin C–associated protein 325–340 V D Q W S T E T I A S H E D I E
Serine proteinase inhibitor 90–103   L R D F S N M A S A E E N Q
14-3-3 ζ 28–41  S V T E Q G A E L S N E E R
Nicastrin 65–78  I S G D T G V I H V V E K E
IL-6 signal transducer 311–324  W S E E A S G T T Y E D R P
The favorable anchor residues at P1, P4, P6, and P9 are underlined. The entire list of naturally processed peptides selected by DQ8 is shown in Supple-
mental Table 1.
Table 3
Examples of naturally processed peptides selected by I-Ag7
Peptide	 	 	 	 	 	 1	 	 	 4	 	 6	 	 	 9
E25B protein 112–126  Y Q T I E E N I K I F E E D A
Cyclophilin C–associated protein 325–340  V D Q W S T E T I A S H E D I E
Actg2 protein 70–84  Y P I E H G I I T N W D D M E
HDL binding protein 20–35  V P Q Q I K V A T L N S E E E N
IL-21 receptor 350–366 I P L A A G Q A V S A Y S E E R D
B lymphocyte antigen CD19 19–33    R P Q K S L L V E V E E G G N
Cathepsin D 65–77   E P V S E L L K N Y L D A
Ndfip 1 protein 84–98  T E A T I P L V P G R D E D F
Transferrin receptor 34–47   S H V E M K L A A D E E E N
Phosphoglycerate kinase 76–89  W E A F A R G T K S L M D E
The favorable anchor residues at P1, P4, P6, and P9 are underlined. The entire list of naturally processed peptides selected by I-Ag7 is shown in 
Supplemental Table 2.
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this MHC molecule (Table 5). Most peptides bound with a rela-
tive affinity in the range of 0.6–5.0 µM, and 2 were poor binders 
(IC50 > 33.0 µM; Table 5). Four peptides tested in this assay were 
previously isolated from I-Ag7 and shown to bind to it (Table 5) 
(13). The relative binding affinity of these 4 common peptides was 
comparable between I-Ag7 and DQ8 (Table 5).
The peptide-binding register of the natural epitopes to DQ8 was 
examined by testing peptides with single amino acid changes in 
order to confirm the usage of preferred anchor residues (Table 6). 
Placing lysine, a strong hindering residue for P1, P4, P6, and P9, at 
different positions in the peptide sequence helped indicate which 
position was normally being used.
E25B peptide. The E25B 112–126 peptide family was selected 
by both DQ8 and I-Ag7. To identify the P9 anchor, each of the 3 
C-terminal acidic amino acids was changed to a lysine. Changing the 
Glu123 and Asp125 to a lysine had no effect on binding to either 
DQ8 or I-Ag7 (Table 6). However, when Glu124 was mutated, the 
peptide bound very poorly to both, which demonstrated that this 
residue was being preferentially used as the P9 anchor. To con-
firm that this was indeed the binding register, i.e., with Glu124, 
the putative P4 (Ile119) or P6 (Ile121) was changed to a lysine. 
A basic amino acid at P4 or P6 also negatively affects binding: 
either change also resulted in a loss of binding (Table 6). (The lack 
of a binding register having Glu123 or Asp125 as the P9 anchor 
residues is explained by unfavorable residues at P4 and/or P6: if 
Glu123 was the P9 anchor, then Lys120 would be the P6 anchor; 
if Asp 125 was the P9 anchor, then Lys120 and Phe122 would be 
the P4 and P6 anchors, respectively.) Of note is that changing the 
multiple C-terminal acidic residues to alanine only resulted in a 
modest decrease in binding to both DQ8 and I-Ag7 — an alanine, 
although not preferred at P9, was well tolerated (10, 11). In the 
case of DQ8, changing the P1 Glu116 to a lysine also resulted in 
about a 4- to 5-fold loss of binding (Table 6). Thus, although DQ8 
prefers acidic amino acids at P1 and P9, the effect on binding is 
more evident for P9 than for P1 (Table 6). Moreover, these muta-
tional analyses taken together established that the E25B 112–126 
peptide binds to both I-Ag7 and DQ8 in exactly the same register.
Table 4
List of naturally processed DQ8 peptides that were also selected by I-Ag7
Peptide	 	 	 	 	 	 	 	 	 1	 	 	 4	 	 6	 	 	 9
Ran 25 kDa ras-related protein 19–34     H D L E V A Q T T A L P D E D D
Lymphocyte cytosolic protein 1 508–519      E D I G G G Q K V N D D
14-3-3 ζ 228–245 W T S D T Q G D E A E A G E G G E N
Ubqln2 protein 81–94     M R Q L I M A N P Q M Q Q L
E25B protein 112–126A     Y Q T I E E N I K I F E E D A
Hnrpr protein 592–601         Y Q D T Y G Q Q W K
SNRPF protein 128–143     Y I R G V E E E E E D G E M R E
Envelope protein 497–512     V S A L E K S L T S L S E V V L
Cytochrome b5 precursor 136–146       Y R H F W A D S K S S
Wbscr5 146–162    K P S T P E S G V E D F E D Y Q N
Small nuclear ribonucleoprotein polypeptide G 48–59       M A T S G Q Q N N I G M
Eef1a1 protein 191–200         V P I S G W N G D N
Translocase of mitochondrial membrane 7 36–50     F T R G A D P G M P E P S V L
Apolipoprotein A-IIA     G S E L Q T Q A K A Y F E K T Q
Elongation factor 1-β homolog 213–225       Y V Q S M D V A A F N K I
G-3-P dehydrogenase 296–309     R V V D L M A Y M A S K E E
Cyclophilin C–associated protein 325–340A     V D Q W S T E T I A S H E D I E
CD23 218–231A    D L K G R L V S I H S Q K E Q D
The peptides are aligned on the basis of the preferred anchor residues at P1, P4, P6, and P9. APeptides that were shown to bind to both DQ8 and I-Ag7.
Figure 2
Acidic amino acid distribution among naturally processed peptides 
selected by I-Ag7 and DQ8. Each peptide was scored for the pres-
ence of either an aspartic acid or glutamic acid residue starting at the 
most C-terminal position, which was assigned position 1 in the figure. 
Thus, by this scheme, the second most C-terminal residue would be 
position 2, the third would be position 3, and so on. Note that peptides 
selected by both I-Ag7 and DQ8 contained acidic amino acids toward 
their C termini. In addition, peptides selected by DQ8 also exhibited 
the biased presence of acidic amino acid toward their N terminus. The 
dotted line represents the background frequency of the presence of 
acidic amino acids.
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MHC II Eα peptide. Three acidic amino acids are found at the C 
terminus of the Eα51–65 peptide: Asp60, Glu62, and Glu65. It 
seemed unlikely that Asp60 or Glu65 could be used as P9 anchors 
since they generated binding registers that contained unfavor-
able residues at P4 and P6 (as described above) (Table 6). Glu62 
emerged as the likely candidate for the P9 anchor and when 
changed to a lysine generated a nonbinding peptide (Table 6). The 
binding register was further ascertained by mutating the puta-
tive P4 and P6 (Phe57 and Val59, respectively) to a lysine — both 
changes resulted in a complete loss of binding (Table 6). Note that 
changing the amino acids at P4 and/or P6 singly to an alanine did 
not have a noticeable affect on binding, since these residues are 
acceptable at either of these positions. Also, changing the acidic P1 
anchor (Asp54) to a lysine or alanine only slightly affected binding; 
however, an alanine at P1 in conjunction with P9 reduced binding 
10-fold (Table 6). This was consistent with the results with the E2B 
peptide; i.e., an acidic residue at P9 contributed more to binding 
than the same residue at P1.
Superoxide dismutase 1 peptide. In the superoxide dismutase 1 
peptide, Glu101 was the P9 anchor; changing this to lysine gener-
ated a nonbinding peptide (Table 6). Mutating the P9 Glu101 to 
an alanine decreased binding about 3-fold, and this was enhanced 
when the P1 Asp93 was also changed to an alanine (>15-fold loss 
of binding) (Table 6). Substituting only the P1 Asp93 to a lysine 
had a very modest effect on binding. The register was further con-
firmed by changing the P6 Val98 to a lysine, which again resulted 
in a complete loss of binding (Table 6).
TRAIL receptor 2 peptide. In the case of the TNF-related apoptosis-
inducing ligand (TRAIL) receptor 2 peptide, the only C-terminal 
acidic amino acid was a Glu376, which when mutated to a lysine 
resulted in about a 4-fold loss of binding (Table 6). Changing the P1 
Tyr368 to lysine or an alanine had a small negative effect, but replac-
ing both P1 and P9 by lysines decreased binding about 15-fold, 
which indicates a cooperative interaction between the P1 and P9 
anchor residues (Table 6).
Nicastrin peptide. In the nicastrin peptide, changing the P9 
Glu76 to a lysine lowered binding about 18-fold, but the same 
mutation at P1 (Asp68→Lys) resulted in a complete loss of 
binding (Table 6). Thus, the P1 
acidic anchor contributed more 
to binding affinity than the P9 
acidic residue (Table 6).
Discussion
The diabetogenic-propensity 
class II MHC molecules exhibited 
a very high degree of specificity 
with regard to natural peptides 
selected during processing of the 
proteins. Neither DQ8 nor I-Ag7 
molecules were promiscuous in 
terms of the peptides selected dur-
ing processing, and for both, the 
P9 anchor played the dominant 
role in establishing the register 
of peptide binding. These charac-
teristics explain the commonali-
ties of peptide selection between 
the murine and human class II 
molecules, which are structurally 
similar at the P9 anchor site but are unique at the other positions. 
Also worthy of emphasis is the presence of multiple C-terminal 
acidic residues — 39% and 46% of peptide families from DQ8 and 
I-Ag7, respectively, contained more than 1 C-terminal acidic resi-
due, some in pairs and others separated by 1 amino acid (Figure 2). 
In addition, for DQ8 molecules, the P1 anchor (mostly aspartic 
or glutamic acid) cooperated with the P9 acidic amino acid to 
increase binding affinity (Table 6).
We emphasize these results because other studies, including 
an early one from our laboratory (34), claimed the contrary, 
that there was a noticeable lack of specificity of I-Ag7 or DQ8 
molecules for peptides (24, 30, 31). These data were obtained by 
examining synthetic peptides or phage display libraries thought 
to represent the antigenic epitopes and equivalent to the natural 
peptides. The results indicated that the key primary anchor posi-
tions for DQ8 and I-Ag7 were tolerant to many amino acids, an 
issue which is undisputed. An excellent example supporting this 
argument is the P9 pocket of DQ8 and I-Ag7, which accommo-
dated acidic or small hydrophobic/polar residues. However, the 
results indicated here by the analyses of naturally selected pep-
tides portray a very different outcome characterized by exquisite 
selectivity and an overwhelming bias for the presence of acidic 
amino acids at this position (Figure 3, A and B).
The explanations for this important discrepancy may be along 2 
lines: either during the processing of the proteins to generate the 
peptide-MHC complex, the peptides with nonacidic C-terminal 
residues were not bound (in general the peptides with non–termi-
nal acidic residues tend to bind less well, although this reduction 
is not a striking feature); or if they did bind, they were edited by 
HLA-DM (or H2-DM) and/or lost during the intracellular traf-
ficking of the MHC molecules. Work that is in progress indicates 
that peptides with nonacidic residues dissociated at a higher rate 
from the MHC molecules at neutral pH. Regardless of the expla-
nation, the repertoire of natural peptides represents those that are 
physiologically relevant for the T cell response, which is especially 
important in the case of aberrant immune responses mounted 
against self. (In addition, knowing the sequence of the natural pep-
tides establishes other features important for T cell recognition, 
Table 5
Binding analysis of naturally processed peptides to DQ8
Peptide	 AA	sequence	 Binding	(µM)
	 	 DQ8	 I-Ag7	A
MHC II Eα 51–65 FDGDEIFHVDIEKSE 1.0 –
Superoxide dismutase 1 90–103 AGKDGVANVSIEDR 2.0 –
Cyclophilin C–associated protein 325–340 VDQWSTETIASHEDIE 0.6 3.3
E25B protein 112–126 YQTIEENIKIFEEDA 0.8 0.4
TRAIL receptor 2 364–380 GRFTYQNAAAQPETGPG 1.7 –
Transferrin receptor 334–347 IPVQTISRAAAEKL 3.8 –
Nicastrin 65–78 ISGDTGVIHVVEKE 1.0 –
Na,K-ATPase α-1 subunit 400–413 ADTTENQSGVSFDK >33.0 –
Lamp I 129–144 IYTMDSTTDIKADINK 7.8 –
Apolipoprotein A-II 31–46 GSELQTQAKAYFEKTQ 4.6 1.8
CD23 219–231 DLKGRLVSIHSQKEQD 5.9 3.1
MHC class II antigen, DQ α chain 39–52 YQSYGPSGQYSHEF >33.0 –
Polyubiquitin 6–21 KTLTGKTITLEVEPSD 1.0 –
Serine (or cysteine) proteinase inhibitor 90–103 LRDFSNMASAEENQ 2.4 –
APeptides that were tested for binding in a previous study by Suri et al. (13).
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such as the relevance of flanking residues in the display of the T 
cell receptor contact residues [ref. 35].) The contrasting results 
indicate the problems in depending only on data obtained from 
peptides thought to represent the natural epitopes. Vaccination 
with microbial or autoimmune peptides without knowing their 
display may be a fruitless venture.
Finally, our results provide more evidence, this time direct, of 
the selection of identical epitopes between APCs bearing DQ8 or 
I-Ag7 molecules. Many previous studies identified common pro-
teins (such as glutamic acid decarboxylase, insulin, heat shock 
proteins, etc.) as targets of autoimmunity in NOD mice and 
humans (reviewed in refs. 1, 36). In addition, previous reports 
analyzing T cell responses have indirectly alluded to common 
epitopes that may be displayed by I-Ag7 and DQ8 
(37–39). Our data supports the hypothesis that 
the NOD mouse is highly valid for identification 
of putative pathogenic T cell epitopes and for test-
ing such peptides for their ability to establish dis-
ease-preventive protocols.
Methods
Cell lines, antibodies, and isolation of peptides
The M12.C3 B cell lymphoma was fused to LPS-
activated splenocytes from wild-type NOD (I-Ag7) 
or transgenic NOD.DQ8 (DQ8+I-Ag7–) (40) mice 
to generate the NOD.C3 or NOD.DQ8 cell lines, 
respectively. Usage of mice was approved by the 
Division of Comparative Medicine at Washington 
University (St. Louis, Missouri, USA). This proto-
col generated APC lines on identical genetic back-
grounds, although variation due to chromosomal 
differences between the 2 cell lines was not excluded. 
Both cell lines were maintained in DMEM supple-
mented with 10% calf serum. For isolation of pep-
tides, NOD.C3 and NOD.DQ8 cells were expanded 
in roller bottles to obtain 5 × 109 to 10 × 109 cells. 
Following detergent lysis, the MHC molecules were 
affinity purified using the AG2.42.7 (for anti–I-Ag7) 
or 9.3.F10 (for anti-DQ8) antibodies conjugated to 
sepharose beads, as previously described (13, 14). 
Peptides bound to class II MHC molecules were acid 
eluted using 0.1% trifluoroacetic acid (TFA), sepa-
rated from the class II MHC proteins, dried down, 
and then analyzed by mass spectrometry (MS) as 
described below.
Generation of soluble DQ8 molecules
Construction of DQ8 expression vector. The cell line 
NOD.DQ8 containing the DQ8 α and β ect-
odomains were cloned into the vector pCR2.1 
(Invitrogen Corp.) and modified by PCR exten-
sion to include the Fos and Jun leucine zipper 
domains. The domains of both DQ8 chains were 
subcloned into the baculovirus expression vector 
pFastBac Dual (Invitrogen Corp.). The Fos and 
Jun leucine zippers were attached to the C termi-
nus of each chain through a polylinker containing 
thrombin cleavage sites (ANLVPRGSTAPS). The α 
chain carries a 6-His-tag at the end of Fos. The β 
chain has a covalently linked human CLIP-containing sequence 
(SKMRMANPLLMQA) attached at its amino terminus by a gly-
cine- and serine-rich linker containing a thrombin cleavage site 
(GGGGSLVPAGSGGGGSGS).
Expression of DQ8 in insect cells. High Five insect cells were infected 
with baculovirus expressing the DQ8 chains. Cells were grown to a 
density of 2 × 106 cells/ml in serum-free medium (JRH Biosciences) 
in baffled flasks before infection at an MOI of 10 and then were 
incubated for 72 hours at 27°C. The clarified medium was con-
centrated and exchanged into 50 mM NaH2PO4 (pH 8.0), 10 mM 
imidazole, and 0.5 M NaCl using 10 kDa Centramate tangential 
flow filtration system (Pall Corp.). The concentrated supernatant 
was passed by gravity over a 5-ml bed of Ni-NTA beads (QIAGEN). 
Figure 3
Distribution of amino acids at the P1, P4, P6, and P9 positions. (A) Peptide binding 
motif for DQ8. The P1 through P9 amino acids of the naturally processed peptides 
listed in Supplemental Table 1 were aligned to identify the preferred residues at P1, 
P4, P6, and P9. (B) Peptide binding motif for I-Ag7. The P1 through P9 amino acids 
of the naturally processed peptides listed in Supplemental Table 2 were aligned to 
identify the preferred residues at P1, P4, P6, and P9.
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The column was washed first with 50 mM NaH2PO4 (pH 8.0), 
0.5 M NaCl, and 50 mM imidazole and then eluted with 50 mM 
NaH2PO4 (pH 8.0), 0.5 M NaCl, and 250 mM imidazole. The frac-
tions containing the DQ8 were pooled and dialyzed to 10 mM 
HEPES, 150 mM NaCl (pH 7.2).
Binding analysis
Briefly, 1.0–1.5 µg of purified baculovirus DQ8/CLIP was treat-
ed with 0.1 units of thrombin to cleave both the zipper tails and 
peptide linker (Novagen) and simultaneously incubated with 
0.125 pmol of 125I-radiolabeled reference hemagglutinin peptide 
Table 6
Mutational analyses of naturally processed peptides to identify the binding register
Peptide	 Sequence	 Binding	(µM)
	 	 DQ8	 I-Ag7	A
E25B protein 112–126	 Y	Q	T	I	E	E	N	I	K	I	F	E	E	D	A 0.8 0.4
	 ----------------------K------ 1.0 0.3
	 ------------------------K---- >33.0 12.0
	 --------------------------K-- 1.7 0.2
	 ------------------------A---- 1.8 0.3
	 ------------------------A-A-- 2.5 0.5
	 ----------------------A-A-A-- 1.7 2.3
	 ------------------K---------- >33.0 9.9
	 --------------K-------------- >33.0 66.0
	 --------K-------------------- 3.8 ND

































The 9-mer binding core mapped for each peptide is underlined. ABinding was tested in a previous study by Suri et al. (13). ND, not determined; NB, non-binder.
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(FESTGNLIAPEYGFKISY), labeled by the chloramine T method, 
as described previously (41), and increasing doses of unlabeled 
peptides in 40 mM 2-[N-Morpholino]ethanesulfonic acid, 150 
mM sodium chloride, pH5.5. The hemagglutinin peptide has 
previously been used as an indicator peptide in DQ8 binding 
assays (26). Binding reactions were incubated for 48 hours at 
37°C in 30- to 32-µl volumes. Complexes were purified from 
free peptide using gel filtration Bio-Spin columns (Bio-Rad Lab-
oratories). The percentage of bound peptide was evaluated by 
gamma counting. The amounts of peptides bound in the reac-
tions were about 15–20% that of the input radiolabeled standard 
peptide. Relative binding data refers to the amounts required to 
inhibit the binding of the reference peptide by 50%. Individual 
binding results with the reference peptide varied less than 10% 
from the averaged value.
Two-dimensional liquid chromatography–MS
MHC peptide extracts from NOD.DQ8 and NOD.C3 lines were 
treated identically. Each was analyzed by on-line reverse phase 
liquid chromatography–MS (RPLC-MS) and MS/MS and addi-
tionally by off-line strong cation exchange (SCX) LC followed by 
on-line RPLC-MS/MS. To avoid cross-contamination of samples, 
both reverse phase (RP) and SCX columns were new and dedicated 
to either NOD.DQ8 or NOD.C3 peptide analysis.
Initially, the dried extracts were resuspended in 60 µl 0.1% TFA, 
desalted, and further purified using 3 ZipTip (Millipore) pipette 
tips containing C18 RP media per the manufacturer’s protocol. 
Three elutions were performed, each using 30 µl 50:50 acetoni-
trile (CH3CN)/H20, in 0.1% TFA, providing 90 µl elution for each 
extract. The eluent was completely dried and resuspended in 55 µl 
3% CH3CN, 97% H20, 0.1% formic acid (solvent A for RPLC).
Five microliters of sample was loaded onto a silica capillary col-
umn with a PicoFrit tip (New Objective Inc.) packed in-house with 
C18 RP material (Delta-Pak, 0.075 × 100 mm, 5 µm, 300 Å; Waters 
Corp.). The gradient, pumped using a Waters CapLC (Waters Corp.), 
was from 0% solvent B (97% CH3CN, 3% H2O, 0.1% FA) to 5% solvent 
B over 3 minutes, then to 50% solvent B over 70 minutes. Eluent 
flow was approximately 5 µl/min and split before the column at an 
approximately 1:25 ratio to maintain a flow rate at the tip of 250 
nl/min. Flow was directed into the entrance of the heated capillary 
of an LCQ-Deca Quadrupole ion-trap mass spectrometer (Thermo 
Electron Corp.) equipped with a custom-built nanospray source.
MS and dependent-scan mode MS/MS were performed using 
the mass spectrometer under the control of Xcalibur 1.3 software 
(Xcalibur Software Inc.). For MS, the scan range was 600–1,400 
mass/charge ratio (m/z) in the profile mode. For MS/MS, a scan 
range of 600–1,400 m/z in centroid mode was used for the MS, 
and the MS/MS range was from 30% of the mass/charge ratio of the 
parent ion to 2,000 m/z. The isotope clusters of parent ions were 
dynamically selected and isolated with a 2.0-m/z window. The col-
lision energy was set to 28% of the maximum, which is approxi-
mately 5 eV. For detection of peptides, the mass spectrometer 
selected peptides based on their signal intensity. In such experi-
ments, the first and second most abundant ions were analyzed in 
the first run, and the third and fourth most abundant ions were 
analyzed in a subsequent run.
After RP-LCMS and MS/MS analysis, the remainder of the 
sample (∼40 µl) was dried to completion and resuspended in 20 µl 
solvent C (30% acetonitrile; pH to 3.5 with FA). Ten microliters 
was analyzed by SCX using an Ultra-Plus II LC with flow split to 
5 µl/min and a PolySulfoethyl column (15 cm × 320 µm; Micro-
Tech Scientific Inc.). The gradient was from 0% solvent D (30% 
CH3CN, 01% FA, 1M ammonium acetate) to 25% solvent B in 35 
minutes, to 50% solvent B at 50 minutes, to 100% solvent B at 65 
minutes. Ten 7-minute fractions were collected, dried down, and 
resuspended in 10 µl 3% CH3CN, 0.1% formic acid. Five microli-
ters was injected for on-line RPLC electrospray ionization–MS as 
described above using data-dependent scanning fragmentation of	
the 2 most abundant ions.
All product ion spectra were analyzed, and peptide sequences 
were determined automatically using Mascot software (Matrix 
Science Ltd.). All the automatically determined sequences were 
manually verified against the experimental product ion spectra. 
The relative abundance of each peptide ion was calculated as previ-
ously described (13, 14).
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